Skip Label
cytokines in inflammatory process banner

IL-36 in Inflammatory Skin Diseases

Uncontrolled activation of the IL-36 pathway by overexpression of agonists or, in some cases, loss-of-function mutation in the antagonist can drive pathogenic pathways underlying select inflammatory skin diseases.1-7

IL-36 in Inflammatory Process

Learn more about the role of IL-36 in Inflammatory Skin Diseases:

References

  1. Johnston A, et al. J Allergy Clin Immunol. 2017;140(1):109-120. 

  2. Ganesan R, et al. MAbs. 2017;9(7):1143-1154.

  3. Marrakchi S, et al. N Engl J Med. 2011;365(7):620-628.

  4. Onoufriadis A, et al. Am J Hum Genet. 2011;89(3):432-437. 

  5. Sugiura K, et al. J Invest Dermatol. 2013;133:2514-2521. 

  6. Bassoy EY, et al. Immunol Rev. 2018;281:169-178. 

  7. Gabay C, et al. J Leukoc Biol. 2015;97:645-652.